Aktie A2N5Z5 IRRC CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen IRRC Corporation

Aktien

A2N5Z5

JP3105230001

7325

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 18.04.2024 		% 5 Tage % 1. Jan.
728 JPY +1.96% Intraday Chart für IRRC Corporation -5.21% +12.69%
2023 IRRC Corporation (TSE:7325) hat die Übernahme von 80,9% der Anteile an Life Assist Co., Ltd. von Orix Life Insurance Corporation abgeschlossen. CI
2023 IRRC Corporation (TSE:7325) kündigt einen Aktienrückkauf für 200.000 Aktien an, was 2,38% für ¥160 Millionen entspricht. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
Henlius Biotech, Inc. - Results from Four Phase 1/2 Clinical Trials of Henlius Innovative Products Released at 2023 ESMO Asia
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
IRRC Corporation completed the acquisition of 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation.
IRRC Corporation announces an Equity Buyback for 200,000 shares, for ¥160 million.
IRRC Corporation authorizes a Buyback Plan.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
IRRC Corporation's Equity Buyback announced on February 14, 2023, has closed with 300,300 shares, representing 3.48% for ¥228.63 million.
IRRC Corporation signed a basic agreement to acquire a 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation for approximately ¥400 million.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
IRRC Corporation Reports Earnings Results for the Nine Months Ended March 31, 2023
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology
IRRC Corporation announces an Equity Buyback for 500,000 shares, representing 5.74% for ¥400 million.
IRRC Corporation authorizes a Buyback Plan.
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
IRRC : Pennsylvania Takes Next Step Toward Cap-and-Trade Amid Resistance
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2N5Z5 Aktie
  4. Nachrichten IRRC Corporation
  5. Andere Sprachen